ANI Pharmaceuticals, Inc. (ANIP)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$71.23-1.06%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · ANIP
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 978.4 | 883.4 | 614.4 | 486.8 | 316.4 | 216.1 | 208.5 | 206.5 | 201.6 | 176.8 | 128.6 | 76.3 | 56.0 | 30.1 | 20.4 | 0.4 |
| Total Revenues | 14.7 | 12.5 | 16.0 | 8.7 | 0.5 | — | — | 206.5 | 201.6 | 176.8 | 128.6 | 76.3 | 56.0 | 30.1 | 20.4 | 0.4 |
| Cost of Revenues | — | — | — | — | — | — | 87.2 | 63.2 | 73.0 | 79.0 | 48.8 | 12.7 | 11.5 | 10.0 | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 324.8 | 317.7 | 249.6 | 161.7 | 124.0 | 84.3 | 65.0 | 55.8 | 44.1 | 31.6 | 27.8 | 21.2 | 17.9 | 16.4 | — | — |
| R&D Expenses | 49.9 | 51.7 | 44.6 | 34.3 | 22.3 | 11.4 | 16.0 | 19.8 | 15.4 | 9.1 | 2.9 | 2.9 | 2.7 | 1.7 | 1.2 | 44.2 |
| Operating Income | 150.4 | 111.1 | 0.6 | 47.0 | (35.3) | (39.8) | (16.0) | 16.4 | 35.4 | 28.3 | 20.1 | 32.7 | 20.0 | 0.9 | (1.6) | — |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.5 | 1.3 | 0.7 |
| Interest & Investment Income | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.3 | 0.7 |
| Asset Writedown | — | 0.8 | 7.6 | 0.0 | 0.6 | 2.4 | 0.4 | — | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | 142.6 | 95.8 | (22.2) | 19.9 | (62.7) | (56.1) | (26.0) | 3.2 | 20.1 | 16.3 | 8.7 | 21.7 | 19.4 | 0.1 | (1.6) | — |
| Income Tax Expense | 34.3 | 17.5 | (3.7) | 1.1 | (14.8) | (13.5) | (3.4) | (2.9) | 4.6 | 17.4 | 4.7 | 6.4 | (9.4) | 0.0 | (0.0) | 0.0 |
| Net Income | ||||||||||||||||
| Net Income | 108.0 | 78.3 | (18.5) | 19.0 | (48.0) | (43.0) | (22.5) | 6.1 | 15.5 | (1.1) | 3.9 | 15.4 | 28.7 | 0.3 | (8.5) | (51.6) |
| Per Share | ||||||||||||||||
| Basic EPS | 5.10 | 3.50 | (1.04) | 0.86 | (3.05) | (3.40) | (1.88) | 0.51 | 1.31 | (0.09) | 0.34 | 1.34 | 2.61 | — | (1.27) | (3.15) |
| Diluted EPS | 4.93 | 3.32 | (1.04) | 0.85 | (3.05) | (3.40) | (1.88) | 0.50 | 1.30 | (0.09) | 0.34 | 1.32 | 2.59 | — | (1.27) | (3.15) |
| Revenue per Share | 0.67 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 21.2 | 20.1 | 19.3 | 18.0 | 16.3 | 12.6 | 12.0 | 11.8 | 11.7 | 11.5 | 11.4 | 11.4 | 10.9 | — | 21.8 | 16.4 |
| Diluted Weighted Avg Shares | 21.9 | 21.2 | 19.3 | 18.2 | 16.3 | 12.6 | 12.0 | 12.0 | 11.8 | 11.5 | 11.6 | 11.6 | 11.1 | — | 21.8 | 16.4 |
| Supplemental | ||||||||||||||||
| EBITDA | — | 202.5 | 68.3 | 106.8 | 21.7 | 7.5 | 28.6 | 61.0 | 69.1 | 56.3 | 42.4 | 39.6 | 23.9 | 2.0 | (1.0) | — |
| EBIT | 150.4 | 111.1 | 0.6 | 47.0 | (35.3) | (39.8) | (16.0) | 16.4 | 35.4 | 28.3 | 20.1 | 32.7 | 20.0 | 0.9 | (1.6) | — |
| Effective Tax Rate | 24.0% | — | — | 5.5% | 23.6% | 24.0% | 13.1% | -93.0% | 22.7% | 106.6% | 54.7% | 29.3% | -48.3% | 15.9% | 2.2% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.